Insider Trading November 11, 2026 10:31 PM

Core Scientific Director Eric Weiss Buys $97,979 in Shares as Stock Trades Below Purchase Price

The insider purchase comes amid a 36% six-month decline and mixed analyst views on the bitcoin miner's transition.

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
CORZ

Core Scientific director Eric Stanton Weiss purchased 6,000 shares of the company's common stock on September 15, 2026, at $16.33 per share, for a total of $97,979, according to a recent filing. Following the transaction, Weiss directly holds 265,262 shares. The purchase occurred as Core Scientific's stock trades at $14.57, below Weiss's purchase price, after a six-month decline of 36%. The stock appears overvalued relative to its Fair Value according to an analysis, and its beta of 5.56 indicates high volatility. In other news, Core Scientific reported strong third-quarter 2026 earnings with colocation revenue of $215 million, up from $135 million, and adjusted EBITDA of $134 million, more than tripling from $41 million. Despite these results, the stock dipped as investors weighed significant capital requirements and the company's ongoing transition away from Bitcoin mining. Analysts have mixed views: Citizens reiterated a Market Outperform rating with a $30 price target, while Craig-Hallum lowered its price target from $35 to $25 but maintained a Buy rating, citing concerns about securing air permits in Texas.

Core Scientific Director Eric Weiss Buys $97,979 in Shares as Stock Trades Below Purchase Price
CORZ
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Director Eric Weiss bought 6,000 shares at $16.33, totaling $97,979, increasing his direct holdings to 265,262 shares.
  • The purchase occurred as Core Scientific's stock trades at $14.57, down 36% over six months, and appears overvalued relative to Fair Value with a beta of 5.56.
  • Third-quarter 2026 results showed colocation revenue of $215 million and adjusted EBITDA of $134 million, but the stock dipped on capital requirements and the transition away from Bitcoin mining.
  • Analyst actions were mixed: Citizens maintained a $30 target with Market Outperform, while Craig-Hallum cut its target to $25 but kept a Buy rating.

Core Scientific, Inc. (NASDAQ:CORZ) director Eric Stanton Weiss acquired 6,000 shares of the company's common stock on September 15, 2026, at a price of $16.33 per share, for a total transaction value of $97,979, according to a recent regulatory filing. The purchase leaves Weiss with a direct holding of 265,262 shares of Core Scientific common stock.

The insider buy comes at a time when Core Scientific's shares are trading at $14.57, below the price Weiss paid. The stock has faced a challenging six-month period, declining 36% over that span. According to an analysis, the stock currently appears overvalued relative to its Fair Value estimate. A noted tip also highlights that the stock price movements are quite volatile, as reflected in the company's beta of 5.56.

In other recent developments, Core Scientific reported significant growth in its third-quarter 2026 earnings. The company saw a sharp increase in revenue and profitability, with colocation revenue climbing to $215 million, up from $135 million in the previous quarter. Adjusted EBITDA also more than tripled, reaching $134 million, a notable rise from $41 million. Despite these strong financial results, Core Scientific's stock experienced a slight dip as investors considered its significant capital requirements and ongoing transition away from Bitcoin mining.

Analyst opinions have also been in focus. Citizens reiterated its Market Outperform rating for Core Scientific, maintaining a price target of $30. The firm highlighted the increasing flow of Core Scientific's 1.1 GW contracted portfolio through its profit and loss statement. Meanwhile, Craig-Hallum adjusted its price target for Core Scientific from $35 to $25 but kept a Buy rating. The adjustment was due to concerns about the company's ongoing efforts to secure air permits in Texas, which are considered low-risk and expected to be resolved by December.

The insider transaction provides a data point for investors assessing internal confidence, though the stock's volatility and capital needs remain key considerations. The mixed analyst actions and the company's transition away from Bitcoin mining continue to shape the investment narrative.

Risks

  • The stock's high volatility, indicated by a beta of 5.56, could lead to significant price swings.
  • Core Scientific faces significant capital requirements and an ongoing transition away from Bitcoin mining, which may pressure financial flexibility.
  • Uncertainty around securing air permits in Texas could affect operations, though the issue is considered low-risk and expected to be resolved by December.

More from Insider Trading

Ambiq Micro CTO Offloads $421,942 in Stock as Shares Extend Rally Nov 11, 2026 QuantumScape CTO Offloads $610,524 in Shares as Stock Hovers Near 52-Week Low Nov 11, 2026 Workday Director David Duffield Offloads $18.6 Million in Stock Under Prearranged Plan Nov 11, 2026 Ciena CEO Offloads Nearly $1 Million in Stock Under Pre-Set Trading Plan Nov 11, 2026 Cooper Companies Director Kurzius Buys $549,320 in Stock at a Discount Nov 11, 2026